XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair
about
Deficient expression of DNA repair enzymes in early progression to sporadic colon cancerHIV-1 TAR miRNA protects against apoptosis by altering cellular gene expressionVirtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interactionThe XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways.Other proteins interacting with XP proteins.Transcriptional Gene Silencing (TGS) via the RNAi Machinery in HIV-1 InfectionsDissecting the molecular pathways of (testicular) germ cell tumour pathogenesis; from initiation to treatment-resistance.HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer.Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cellsExpression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapyInhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.The determination of relationship between "excision repair cross-complementing group 1" (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer.Low-fidelity alternative DNA repair carcinogenesis theory may interpret many cancer features and anticancer strategies.Synthesis, characterization and cellular location of cytotoxic constitutional organometallic isomers of rhenium delivered on a cyanocobalmin scaffold.PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines.Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links.Enhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells.The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.DNA repair pathways and cisplatin resistance: an intimate relationship
P2860
Q21195898-886A00DF-7143-44C5-BCF3-E0E89DB6D2C4Q21245193-8EE98B86-92C3-437A-8BC0-AB6BCA3EE6CEQ28484387-6873B84C-F389-41B6-8758-0A2A3AD05405Q30919478-45778171-F61D-4464-90E4-94375271BC64Q33404215-42DCCB92-DF3E-4AAE-ABA5-3FE6B199E0F0Q33565167-DAB7540F-254D-4F36-B474-C8F3DDEDA4DAQ33896475-25E6B516-E95F-4B7C-9D39-01987E8C47C0Q34216446-D258DB89-5F98-4AAA-B237-FF598B05C02EQ34722650-A04F4FBC-6475-4A0F-98AF-DF20F743CC9CQ35223337-549D5DC6-4B94-4EF5-9479-CF096FA16336Q35686424-8CA6ED3B-8DCA-46D9-A570-86B7A3BA0198Q36557333-7EC920B4-1070-45EA-8BCB-896CA4847F18Q37336111-FBFF0EFE-7645-46FF-989B-0A4B30589EBBQ37969770-F13640B5-E0AA-4F43-BD1E-ACBB9BCC495CQ38335339-8C8D9648-6CB9-4711-921E-552F585728D8Q38868797-2B449EBF-584B-470C-8974-2A1F65648F2FQ38898572-86B09EF1-7B81-419B-8D7D-5292CF474365Q39437808-F1B8FC78-9912-4ABC-8FD8-D1D609F9F47FQ39686779-77C69392-049C-4704-A730-A9F5A2926A04Q39711077-207BB0FB-2644-4E04-88A4-04D0E37B4054Q39807128-DE4C73CE-5B0D-4487-9584-AF76D0F0F6ABQ49479651-5DEB5B88-F6F8-4EFD-A3B9-36040D4FA20AQ53775795-CD3CD93D-FD8C-464B-9698-E79922BB75FFQ58699219-0AFAC388-0F70-48B2-A14F-A30AB3BFB1D9
P2860
XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@ast
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@en
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@en-gb
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@nl
type
label
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@ast
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@en
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@en-gb
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@nl
prefLabel
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@ast
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@en
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@en-gb
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@nl
P2093
P1476
XPA versus ERCC1 as chemosensi ...... omologous recombination repair
@en
P2093
Beate Köberle
Claire J McGurk
John R Masters
Karen Higginbottom
Michele Cummings
Oscar Gee-Wang Wong
R Timothy D Oliver
P304
P356
10.1016/J.BCP.2006.04.025
P407
P577
2006-07-14T00:00:00Z